Designing and Testing a Novel Drug Targeting the Distinct Metabolic Roles of the Isoforms of PPARGamma
ISEF · 2017 Translational Medical Science
Overview
The obesity pandemic affects 36.5% of the US adult population and exacerbates the risk for deadly comorbidities including Type II Diabetes (T2DM). Current obesity and T2DM therapeutics are nonviable because they are ineffective or toxic. One class of T2DM drugs called TZDs improves insulin-sensitivity by augmenting the activity of PPARGamma, a transcription factor regulating fat function and metabolic homeostasis. However, TZDs cause side effects ranging from weight gain to osteoporosis due to the overactivation of PPARGamma. It was shown last year that the two versions of PPARGamma have distinct roles in regulating adipocyte plasticity. PPARGamma1 upregulates beneficial catabolic genes, while PPARGamma2 potently induces lipid synthesis and TZDs’ side effects, suggesting developing isoform-specific therapies for obesity and T2DM. In the present study, these results were further expanded with QPCR analyses and RNA-sequencing analyses for two human cohorts that identified the role of PPARGamma2 in obesity and the beneficial role of PPARGamma1 in lipid catabolism. Thus, limiting PPARGamma2 function may deter obesity and alleviate TZDs’ poor therapeutic viability. Subsequently, a novel small molecule was designed to act as a competitive inhibitor for only PPARGamma2 activity. Oil-Red-O staining and QPCR analyses revealed that the drug reduced PPARGamma2 activity but minimally affected PPARGamma1 activity. It was able to effectively reduce adipogenesis and modify adipocyte morphology while simultaneously decreasing the activity of deleterious genes. This study, therefore, further distinguishes PPARGamma’s isoforms. It also showcases a therapeutic design limiting only PPARGamma2 function that may prove effective in improving T2DM treatments and combating obesity.
Competition history
- ISEF 2017
Resources
Related projects
ISEF · 2018
Identification of Novel Drivers of Insulin Resistance and Type 2 Diabetes in the Skeletal Muscle Tissue of Non-Obese Individuals Using a Multi-Omics Approach
ISEF · 2025
Discovery and Structure-Based Optimization of Highly Selective PTP1B Inhibitors: A Multi-Stage in silico Workflow Integrating Machine Learning for Ligand-Based Virtual Screening and Molecular Docking & Dynamics Simulations To Enhance Insulin Sensitivity in Type-2 Diabetes
ISEF · 2014
Enhancing Pancreatic Islet Function in an Obese Mouse Model
ISEF · 2016
The Molecular Basis of the Transdifferentiation of Embryonic Chick Limb Chondrogenic Precursors into a Beige Fate
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair